（原标题：从厌学到复学｜08 如何从"监工"到"盟友"，让孩子愿意聊学习） 孩子刚显露厌学情绪时，家长的烦恼往往不止"他不肯学"，更有"他不肯说"。不少面临孩子厌学问题的 家长都有这样的困扰：问作业，孩子低头沉默；提考试，孩子转身关门；即便只是一句"今天上课怎么 样"，换来的也可能是"别烦我"。 其实，孩子对"学习话题"如此抗拒，源于他们心里藏着一个隐性逻辑："以前每次聊学习，不是被批 评'不够努力'，就是被催'快点进步'。" 所以，我们要学会用"非批判性对话"，拆掉孩子这层"防御 壳"——让他们相信，和爸妈聊学习，不会被评价、不会被比较，只会被看见、被接纳。 分享5个沟通技巧，帮我们在和孩子聊天时，让对话成为"桥梁"而非"战场"。 评价容易让孩子立刻进入"辩解模式"，比如他可能会说"我就是累了"；而事实描述能让他聚焦具体问 题，比如他或许会说"可能是刚才有点走神"。 就像医生不会先说"你真不爱惜身体"，而是先讲"你的血压有点高"——不带评判的观察，才更能让人愿 意听下去。 二、把"为什么"换成"怎么了" 想了解孩子厌学的隐情，别问"你为什么就是不想学？"因为这会让孩子捕捉到提问背后的潜台词 ——"你有问题" ...

Group 1: Core Insights - The article discusses the historical significance and cultural heritage of Buddhist pagodas in Suzhou, highlighting their evolution from the Tang dynasty to the Qing dynasty, with a peak during the Song dynasty [2][3][4]. Group 2: Historical Context - Suzhou, known as the "City of Pagodas," has over 100 historical pagodas, with more than 20 well-preserved today, reflecting its rich cultural and economic history [2][3]. - The article mentions the flourishing of Buddhism in Suzhou during the Tang and Song dynasties, with significant temple constructions and restorations [2][4]. Group 3: Notable Pagodas - The Beisi Pagoda, rebuilt in 1153, stands at 76 meters and is a prominent landmark in Suzhou [3]. - The Yunyan Pagoda, also known as the Tiger Hill Pagoda, was built in 961 and has undergone several restorations due to damage from fires and military actions [4]. - The Ruiguang Pagoda, originally built in 1004, has been restored multiple times and features a unique architectural style [4][5]. Group 4: Artifacts and Discoveries - Significant artifacts were discovered during the restoration of the Yunyan Pagoda, including a treasure trove of Buddhist relics such as sutras, sculptures, and ceremonial items [7][14]. - The Ruiguang Pagoda also yielded valuable artifacts, including colored statues and sutras from the Tang and Song dynasties, which are crucial for studying the spread of Esoteric Buddhism in southern China [14][20].

Core Viewpoint - Humanwell Healthcare reported a year-on-year increase in net profit and net profit after deducting non-recurring gains and losses for the first half of 2025, despite a decrease in operating revenue due to structural reforms in the pharmaceutical industry and a focus on core business optimization [1] Financial Performance - The company achieved operating revenue of 12.064 billion yuan, with a net profit attributable to shareholders of 1.155 billion yuan, representing a year-on-year growth of 3.92% [1] - The net profit after deducting non-recurring gains and losses was 1.130 billion yuan, up 3.81% compared to the same period last year [1] - Operating revenue decreased by 6.20% year-on-year, primarily due to structural reforms in the pharmaceutical payment sector [1][6] - The asset-liability ratio decreased from 43.32% at the beginning of the reporting period to 43.00%, indicating improved capital structure and operational efficiency [6] Core Business Development - Humanwell's pharmaceutical subsidiaries maintained stable growth, particularly in the anesthetics sector, with significant product growth in various anesthetic drugs [2] - The company is a leader in the domestic market for sex hormone drugs, with a strong global market share in progesterone raw materials and a unique product line in the formulation sector [2] - The company is actively expanding its product offerings in the field of sex hormone drugs and has faced temporary profit pressure due to increased fixed asset depreciation from new production facilities [2] Innovation and R&D - The company is focusing on a dual-driven strategy of innovation and global expansion, with over 2,000 R&D personnel and significant investments in innovative drug development [4] - In the first half of 2025, R&D expenses exceeded 700 million yuan, with 14 new products approved, covering various therapeutic areas [4] - Progress in biopharmaceuticals includes the completion of production site verification for a new drug and multiple new drug projects approved for clinical trials [4] International Expansion - Humanwell has established a collaborative market presence in the U.S., Europe, and Africa, with ongoing challenges in the U.S. generics market due to local competition and tariffs [5] - The company is laying the groundwork for deeper market penetration in Europe through partnerships and product approvals in Germany and France [5]

（原标题：健康营销进入 "全域时代"：京准通凭什么成为品牌增长引擎？） 过去数年，中国正式迈入"大健康" 时代 —— 健康理念不再局限于 "治病就医"，而是深度融入衣食住行、生活方式选择，乃至身心调养的全场 景，健康消费由此成为全民刚性需求。据行业预测，2030 年中国健康产业规模将达 16 万亿元，巨大的市场潜力背后，品牌却普遍陷入营销突围 困境。 一方面，消费群体代际更迭带来沟通难题。年轻一代成为健康消费新主力，他们习惯在碎片化渠道中获取信息，对传统说教式营销天然排斥，更 青睐有趣、有互动、有价值观共鸣的内容；但多数健康品牌缺乏对年轻群体需求的精准洞察，要么内容生硬无法引发共情，要么渠道选错导致资 源浪费，难以在年轻消费者心中建立品牌认知。另一方面，全渠道运营陷入"分散低效" 陷阱：线下宣传覆盖有限、成本高企，难以精准定位目标 人群；线上流量则分散在各平台，品牌既无法整合资源形成合力，又因平台属性差异难以实现营销效果最大化。 依托京准通打造的"全域资源整合 - 人群资产沉淀 - 精细化运营 - 京东站内转化" 全链路闭环，为健康品牌提供了从流量到销量的增长路径。 在资源端，京东已与腾讯系、巨量引擎、快手、 ...

Core Viewpoint - The company continues to implement its "Big Health + Big Business" dual main business development strategy, focusing on the steady growth of its health sector and the transformation of its commercial sector [2][7] Group 1: Health Sector Development - The company aims to expand its pharmaceutical business matrix, focusing on chemical drugs, traditional Chinese medicine, and medical devices, while enhancing marketing and internal cost management [3] - The Dikan Chinese Medicine segment is progressing with major product planning and certification, leading to increased sales and competitive advantages in the traditional Chinese medicine market [3] - The Huake Reproductive Hospital is enhancing its IVF services and exploring related business extensions, such as establishing a miscarriage prevention center and developing traditional Chinese medicine for fertility [4] Group 2: Commercial Sector Transformation - The company is actively pursuing commercial transformation by leveraging its historical strengths and adapting to current market demands through brand upgrades and diversified operations [5] - The company has set goals for upgrading its commercial entities, focusing on creating diverse consumer experiences and enhancing market competitiveness [5][6] - The company has received approval for 10 low-altitude logistics routes to support high-efficiency goods delivery and emergency services [6] Group 3: Future Outlook - The company anticipates that the ongoing implementation of its dual business strategy will lead to a stabilization and potential recovery in future performance [7]

Group 1 - Huawei and SAIC have launched the first SUV of the Shangjie brand, the Shangjie H5, with a starting pre-sale price of 169,800 yuan [2] - The Shangjie H5 has received over 50,000 small orders within 18 hours of its pre-sale, marking a significant entry for Huawei's HarmonyOS driving technology into the budget electric vehicle market [2] - The Shangjie H5 is positioned against competitors like Leapmotor C11, Xpeng G6, and Deep Blue S07, offering advanced Huawei technology at a more accessible price point [2] Group 2 - SAIC Group reported a 43.49% year-on-year increase in new energy vehicle sales, totaling 763,500 units from January to July this year [3] - The Shangjie H5 features both range-extended and pure electric powertrains, with the range-extended version offering a maximum range of 1,360 km and the pure electric version providing up to 655 km [3] - The Shangjie H5 is developed based on the SAIC Roewe ES39 model and utilizes the SAIC Star Cloud pure electric platform, benefiting from SAIC's supply chain [3] Group 3 - Over 1,500 dealers, including luxury brand 4S stores like Porsche and Volvo, have expressed interest in joining the Shangjie brand [4] - The official launch event for the Shangjie H5 is scheduled for September 23, with potential price adjustments based on continued demand [4] - The Shangjie brand faces challenges in brand recognition and consumer trust regarding quality control and after-sales service [3][4]

（原标题：寒武纪当了7分钟"股王" 此前一月内股价累计涨幅高达120%） 8月27日午后，A股市场上演历史性一幕：AI芯片龙头寒武纪(688256.SH)股价持续攀升，最高触及1464.98元/股，超越素有"股王"之称的贵州茅台 (600519.SH)，成为A股市场股价最高的个股。 从13:38到13:44，寒武纪股价7分钟内两次超越贵州茅台。也就是说，寒武纪只当了7分钟的A股股王，之后就被茅台赶下来了。 截至下午1点56分，寒武纪股价报1417.60元/股，上涨6.67%；而贵州茅台股价为1459.02元/股，下跌1.52%。 截至下午收盘，寒武纪股价报1372.10元/股，当日每股上涨43.10元，上涨幅度为3.24%。 寒武纪此次股价超越贵州茅台，引发市场广泛关注。今年以来，寒武纪股价走势强劲，尤其是在7月25日至8月26日期间，累计涨幅高达 121.42%。 8月22日，寒武纪股价突破1200元大关，市值也随之突破5000亿元。 昨天，寒武纪收盘价为1329元/股，距离贵州茅台当日收盘价1481.61元/股已相差不远。 不过，也有市场人士指出，股价的短期波动受多种因素影响，虽然寒武纪此次股价一度超越贵 ...

免责声明：本文观点仅代表作者本人，供参考、交流，不构成任何建议。 8月27日讯，蔚来（NIO.US）美股股价在过去60个交易日内累计飙升90%，远超同期恒生指数9%的涨 幅，创下去年10月初以来新高。8月26日单日涨幅超11%，盘中最高触及6.83美元，收盘报6.70美元，市 值回升至150亿美元。摩根士丹利发布最新研报，维持蔚来"增持"评级，H股目标价50.7港元（约6.5美 元），较当前股价仍有上行空间。 经观汽车 ...

（原标题：半年报出现乱码 瑞丰银行回应：系不同设备PDF阅读器差异） 经济观察报 记者 牛钰 胡群 8月26日晚间，瑞丰银行（601528.SH）发布了2025年半年度报告。8月27日早上，经济观察报记者发 现，从新浪财经和巨潮资讯网等三方平台下载的瑞丰银行半年报，以及在Wind平台的瑞丰银行半年报 原文链接中，均有几十页显示为"乱码"。 图片来源：Wind 随后，上述工作人员回拨电话称，目前通过不同的设备打开半年报文件时确实存在显示不同的情况，通 过手机端Wind打开公告链接时亦部分显示乱码，但通过电脑端Wind查阅时正常显示，可能跟每个设备 自带不同的PDF阅读器有关，目前正在积极地解决问题。 经济观察报记者追问为何其他上市公司的半年度报告没有出现类似的情况？该工作人员回应称："我们 也很奇怪，在上传半年报文件时提交的是PDF文件，一般来说不会出现问题。" 截至发稿时，经济观察报记者发现，乱码问题还未解决。记者通过苹果手机微信端打开的上交所官网、 新浪财经和巨潮资讯网等平台下载的瑞丰银行半年报PDF文件部分页面显示乱码，但用安卓手机微信 端，以及WPS APP打开的同一PDF正常显示。此外，使用不同电脑打 ...

Core Viewpoint - Huayi Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange to support its internationalization strategy and attract more international capital [1][2]. Group 1: Company Overview - Huayi Technology is a leading provider in the automotive testing industry and intelligent driving perception solutions, focusing on the electric and intelligent transformation of vehicles [2]. - The company is expanding into emerging fields such as intelligent driving, humanoid robots, and low-altitude aircraft, showcasing its proactive exploration and layout in these areas [2]. Group 2: Financial Performance - In 2024, Huayi Technology achieved a revenue of 423 million yuan, a year-on-year increase of 20.36%, but reported a net loss of 46.73 million yuan, which widened from the previous year's loss of 16.01 million yuan [3]. - In Q1 2025, the company generated a revenue of 142 million yuan, a year-on-year growth of 39.02%, and turned a profit with a net income of 2.96 million yuan, attributed to increased delivery in intelligent driving business and equipment coming into use [3]. Group 3: Market Position and Strategy - Huayi Technology has established long-term partnerships with major domestic and international automotive manufacturers and suppliers, enhancing its business growth potential [3]. - The company plans to deepen its testing services model and expand into integrated testing, inspection, and certification services, while increasing R&D investment to meet growing customer demands [5]. Group 4: H-Share Listing Process - The H-share issuance and listing plan requires approval from the board of directors, shareholders, and various regulatory bodies, indicating a complex process ahead [4]. - The company must comply with legal and regulatory requirements, including a thorough review of its financial status and governance by relevant authorities [4].